Mizuho analyst Graig Suvannavejh initiates coverage on Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Neutral rating and announces Price Target of $30.
US Stocks Eye Strong Open Despite Powell Jitters: This Analyst Says Market Moves Indicate Investor Confusion
U.S. stocks could strive to shake off the negativity, although Fed Chair Jerome Powell's speech scheduled for Friday remains an overhang.